Beam Therapeutics Inc.
ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING SAME TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE
Last updated:
Abstract:
The disclosure provides compositions comprising novel adenosine base editors (e.g., ABE8) that have increased efficiency and methods of using these adenosine deaminase variants for editing a target sequence.
Status:
Application
Type:
Utility
Filling date:
13 Feb 2020
Issue date:
2 Jun 2022